Enzo Biochem, Inc.
ENZ was delisted on the 17th of April, 2025.
65 hedge funds and large institutions have $82.9M invested in Enzo Biochem, Inc. in 2021 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 11 increasing their positions, 24 reducing their positions, and 13 closing their positions.
8% more capital invested
Capital invested by funds: $76.6M → $82.9M (+$6.33M)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
10% less funds holding
Funds holding: 72 → 65 (-7)
54% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 13
54% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 24
84% less call options, than puts
Call options by funds: $496K | Put options by funds: $3.03M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Advisers
New York
|
+$529K |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$183K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$169K |
| 4 |
Belvedere Trading
Chicago,
Illinois
|
+$86.7K |
| 5 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
+$56.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$1.25M |
| 2 |
JP Morgan Chase
New York
|
-$359K |
| 3 |
TEE
Tibra Equities Europe
London,
United Kingdom
|
-$352K |
| 4 |
Jane Street
New York
|
-$245K |
| 5 |
Renaissance Technologies
New York
|
-$164K |
ENZ Hedge Fund Activity: Q3 2021 in Review
65 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in Enzo Biochem, Inc. (ENZ) for Q3 2021, worth a combined $82.9M — up 8.3% from $76.6M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of ENZ and 6 opened new positions — a net loss of 7 holders — while 24 trimmed existing stakes and 11 added.
The largest buyer was Two Sigma Advisers, adding an estimated $529K. The largest seller was Millennium Management, cutting an estimated $1.25M.
- 65 institutional investors held Enzo Biochem, Inc. (ENZ) as of Q3 2021, down from 72 in Q2 2021.
- Funds reported $82.9M of Enzo Biochem, Inc. stock for Q3 2021, up 8.3% quarter-over-quarter.
- 6 funds opened new Enzo Biochem, Inc. positions in Q3 2021 and 13 closed out, a net change of -7 holders.
- The largest Enzo Biochem, Inc. buyer in Q3 2021 was Two Sigma Advisers, an estimated $529K added.
- The largest Enzo Biochem, Inc. seller in Q3 2021 was Millennium Management, an estimated $1.25M sold.
Based on aggregated 13F filings for Q3 2021.